MetaADEDB 2.0 @ LMMD
eslicarbazepine
(BMPDWHIDQYTSHX-AWEZNQCLSA-N)
Structure
SMILES
O[C@H]1Cc2ccccc2N(c2c1cccc2)C(=O)N
Type(s)
Approved
ATC code(s)
N03AF04
Molecular Formula:
C15H14N2O2
Molecular Weight:
254.284
Log P:
3.2582
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
2
TPSA:
66.56
CAS Number(s):
104746-04-5
Synonym(s)
1.
eslicarbazepine
2.
(10S)-10-hydroxy-10,11-dihydro-5H-dibenzo(b,f)azepin-5-carboxamide
External Link(s)
MeSHC571001
PubChem Compound9881504
CHEMBLCHEMBL315985
DrugBankDB14575
IUPHAR/BPS Guide to PHARMACOLOGY7350
KEGGdr:D09215
Therapeutic Target DatabaseD04QZD
ZINC896938
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainSIDER
2Abdominal bloatingSIDER
3Abdominal discomfortSIDER
4AgitationSIDER
5AlopeciaSIDER
6AmnesiaSIDER
7Anaphylactic shockSIDER
8AngioedemaSIDER
9ApathySIDER
10AphasiaSIDER
11Application site painSIDER
12AstheniaSIDER
13AtaxiaSIDER
14Atrioventricular BlockSIDER
15Attention Deficit DisorderSIDER
16Blood and lymphatic system disordersSIDER
17Blood chloride decreasedSIDER
18Blood cholesterol increasedSIDER
19Bone marrow depressionSIDER
20BradycardiaSIDER
21Burning sensationSIDER
22Chest PainSIDER
23ChillsSIDER
24ConstipationSIDER
25CryingSIDER
26DeafnessSIDER
27DehydrationSIDER
28DermatitisSIDER
29DiplopiaSIDER
30DiscomfortSIDER
31DizzinessSIDER
32DrowsinessSIDER
33Drug toxicitySIDER
34Dry skinSIDER
35DysarthriaSIDER
36DyspepsiaSIDER
37Ear and labyrinth disordersSIDER
38Electrolyte imbalanceSIDER
39EncephalitisSIDER
40EndophthalmitisSIDER
41EosinophiliaSIDER
42EpistaxisSIDER
43Erythema MultiformeSIDER
44ErythemaSIDER
45Facial paralysisSIDER
46FatigueSIDER
47Feeling abnormalSIDER
48Flat affectSIDER
49FlatulenceSIDER
50FlushingSIDER
51FractureSIDER
52GastritisSIDER
53Gastrointestinal PainSIDER
54GingivitisSIDER
55Guillain-Barre SyndromeSIDER
56HeadacheSIDER
57HypersensitivitySIDER
58HypersomniaSIDER
59Hypertensive crisisSIDER
60HypotensionSIDER
61HypothyroidismSIDER
62Hypotonic-hyporesponsive episodeSIDER
63IndurationSIDER
64InfectionSIDER
65InfestationSIDER
66Injection site painSIDER
67Injection site tendernessSIDER
68Instillation site painSIDER
69LethargySIDER
70LeukopeniaSIDER
71LymphadenopathySIDER
72MalaiseSIDER
73MalnutritionSIDER
74Memory impairmentSIDER
75Mood swingsSIDER
76Muscle relaxant therapySIDER
77Musculoskeletal discomfortSIDER
78MyalgiaSIDER
79NauseaSIDER
80NervousnessSIDER
81NeuritisSIDER
82NystagmusSIDER
83Optic NeuritisSIDER
84Osteocalcin increasedSIDER
85OsteopeniaSIDER
86OsteoporosisSIDER
87PallorSIDER
88PalpitationsSIDER
89PancreatitisSIDER
90PancytopeniaSIDER
91PetechiaeSIDER
92PruritusSIDER
93PurpuraSIDER
94RednessSIDER
95ShockSIDER
96SomnolenceSIDER
97Stevens-Johnson SyndromeSIDER
98StrabismusSIDER
99StridorSIDER
100SwellingSIDER
101SyncopeSIDER
102TensionSIDER
103Thermal burnSIDER
104ThrombocytopeniaSIDER
105Thrombocytopenic purpuraSIDER
106TinnitusSIDER
107ToothacheSIDER
108Toxicity to various agentsSIDER
109Transaminases increasedSIDER
110TremorSIDER
111Urinary tract infectionSIDER
112UrticariaSIDER
113VIIth nerve paralysisSIDER
114Vascular purpuraSIDER
115VertigoSIDER
116Visual ImpairmentSIDER
117VomitingSIDER
118Weight decreasedSIDER
119nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120329

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.